Company news
TaiMed Biologics Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan
July 7, 2026
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
May 21, 2026
First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy
July 28, 2022
Important Resolutions of the Company's 2022 General Shareholders' Meeting
May 30, 2022
Announcement of members of the Company's Compensation Committee
May 30, 2022
Announcement of members of the Company's 3rd Audit Committee
May 30, 2022
2022 general shareholders' meeting approved the lifting of non-competition restrictions for directors
May 30, 2022
Announcement of the Company's list of newly elected directors and independent directors
May 30, 2022
Announcement of Change of Board of Directors Chairperson
May 30, 2022
TaiMed Biologics received the official approval letter from US FDA for the pre-approval inspection (PAI) of cGMP monoclonal antibody facility
May 26, 2022
TaiMed Biologics: Enrollment of Phase III Clinical Study Is Complete for Trogarzo Intramuscular Injection (IM)
April 27, 2022
TaiMed Biologics Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory
April 27, 2022
The US FDA completed a pre-approval inspection (PAI) of TaiMed cGMP monoclonal antibody facility with no observation
April 20, 2022
TaiMed Biologics: EMA Approves Supplemental BLA Filing for The Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo
April 13, 2022
Announcement of Change of the Company's CEO (President/General Manager)
April 11, 2022
TaiMed Biologics: The US FDA Approves IND Applicaion for Bi-monthly and Quarterly dosing of TMB-365/TMB-380 Combination for Treatment of HIV Infection
March 31, 2022
Exxpands Its Business Model from Biologic Drug Innovator to Contract Development and Manufacturing Organization (CDMO).
March 11, 2022
Submission of IND Applicaion with the US FDA for Bi-monthly and Quarterly dosing of TMB-365/TMB-380 Combination for Treatment of HIV Infection
March 3, 2022
TaiMed Biologics: The US FDA Approves Supplemental BLA Filing for The Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo
February 23, 2022
Decks
- Citi presentation December 2017
Conference · 37 slides · Dec 12, 2017